Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Pharmacol
मुख्य लेखकों: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2017
विषय:
Special Populations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://ncbi.nlm.nih.gov/pubmed/29106740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1025
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन